In the fast-paced world of healthcare, it can take a lot of work to keep up-to-date with the numerous innovations, trends, and opinions that emerge each year.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh